Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly S Chien

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Nature Communications|November 13, 2024
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trialJuan Jose Rodriguez-Sevilla, Vera Adema, Kelly S Chien, et al.
Leukemia Research|February 21, 2023
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemiaAlex Bataller, Kelly S Chien, Koji Sasaki, et al.
Cancer Medicine|March 18, 2024
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasmsKelly S Chien, Faustine Ong, Kunhwa Kim, et al.
Leukemia|April 2, 2025
Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasmsKelly S Chien, Julie S Braish, Ziyi Li, et al.
Biology|January 21, 2023
Concurrent Mutations in <i>SF3B1</i> and <i>PHF6</i> in Myeloid NeoplasmsZhuang Zuo, L Jeffrey Medeiros, Sofia Garces, et al.
Leukemia & Lymphoma|February 11, 2020
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agentsKelly S Chien, Caleb A Class, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Experimental Hematology|September 23, 2022
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaFaezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, et al.
Leukemia Research|January 31, 2021
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Faezeh Darbaniyan, Rashmi Kanagal-Shamanna, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Nature Communications|November 13, 2024
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trialJuan Jose Rodriguez-Sevilla, Vera Adema, Kelly S Chien, et al.
Leukemia Research|February 21, 2023
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemiaAlex Bataller, Kelly S Chien, Koji Sasaki, et al.
Cancer Medicine|March 18, 2024
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasmsKelly S Chien, Faustine Ong, Kunhwa Kim, et al.
Leukemia|April 2, 2025
Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasmsKelly S Chien, Julie S Braish, Ziyi Li, et al.
Biology|January 21, 2023
Concurrent Mutations in <i>SF3B1</i> and <i>PHF6</i> in Myeloid NeoplasmsZhuang Zuo, L Jeffrey Medeiros, Sofia Garces, et al.
Leukemia & Lymphoma|February 11, 2020
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agentsKelly S Chien, Caleb A Class, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Experimental Hematology|September 23, 2022
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaFaezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, et al.
Leukemia Research|January 31, 2021
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Faezeh Darbaniyan, Rashmi Kanagal-Shamanna, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Pageof 5